Concomitant lipid-lowering and anticoagulation therapy for recurrent venous thromboembolism prevention: A Bayesian meta-analysis.
MedAug 17, 2026 (epub)
Clinical ResearchHematology
Harsini Raaja Sulochana, Yufan Yang, Laura Bindila et al.
✦ AI-curated · Sources linked
In 30 seconds
This Bayesian meta-analysis evaluated the efficacy and safety of combined lipid-lowering therapy (LLT) and anticoagulation (AC) for preventing recurrent venous thromboembolism (rVTE) in 28 studies, including 11 randomized controlled trials. The combination therapy showed a reduced risk of rVTE with a relative risk of 0.73, indicating potential benefits over AC monotherapy.
Key findings
- LLT+AC reduced the risk of rVTE with a relative risk of 0.73 [95% CrI: 0.58; 1.05].
- Post-thrombotic syndrome risk was 17% lower with LLT+AC [RR = 0.83, 95% CrI: 0.40; 1.59].
- Major bleeding risk was 15% lower with LLT+AC [RR = 0.85, 95% CrI: 0.76; 0.96].
- LLT+AC significantly reduced C-reactive protein levels [log SMD = -0.86; 95% CrI: -1.48; -0.08].
Why it matters
Understanding the potential benefits of combining lipid-lowering and anticoagulation therapies can inform clinical decisions regarding venous thromboembolism prevention strategies, particularly in patients at high risk for recurrent events.